



ORIGINAL RESEARCH PAPER

Pathology

LEVEL OF PARASITAEMIA AND ITS RELATION TO HEMATOLOGICAL PARAMETERS AND LIVER FUNCTION AMONG PATIENTS WITH FALCIPARUM MALARIA; A STUDY FROM CENTRAL INDIA.

KEY WORDS: Falciparum Malaria, LFT, Haematological parameters

Dr. Aksharaditya Shukla

M.D, RT, Senior Resident, Dept. of Pathology BMHRC, Bhopal Ex- Resident, Dept. of Pathology, Mahatma Gandhi Memorial Medical College, Indore MP

Prof. Dr. C.V.Kulkarni

M.D, Professor and Head, Dept of Pathology, MGM Medical College, Indore

Dr. Aseem Rangnekar*

M.D, Senior Resident, Department of Microbiology, BMHRC, Bhopal Ex-Resident Dept of Microbiology, MGM medical college Indore *Corresponding Author

ABSTRACT

Introduction: In India, *Plasmodium falciparum* malaria remains a very common infection. Liver involvement in severe *Plasmodium falciparum* infection is mainly responsible for death and disability. The clinical presentation of jaundice often reflects a certain degree of liver damage.

Aim: To study the changes in hematological and hepatic function based on laboratory indices in patients with malaria infected with *P. falciparum*.

Material and Methods: This retrospective study done in department of pathology in a tertiary care hospital in central India. It included data collection from 46 patients diagnosed with *falciparum* malaria. The diagnosis of malaria was confirmed by thick and thin smear examination. Hematological parameters and serum levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and bilirubin (total and direct) as test indicators of liver function were studied with respect to the level of parasitaemia.

Results: Patients with moderate and high parasitaemia (3+ and 4+) had significantly lower hemoglobin, hematocrit, white blood cell count, lymphocytes, and platelets when compared with mild to low (3+ and 2+) parasitaemia. However, neutrophils levels, serum AST, ALT, ALP, and bilirubin (total and direct) were deranged in all patients irrespective of level of parasitaemia.

Conclusion: Monitoring blood parameters and hepatic function enable the clinician to establish reliable and prompt diagnosis to ensure adequate therapeutic interventions and follow up.

Introduction

Malaria is an infectious vector-borne disease having very significant morbidity and mortality rates across the globe.¹ It is caused by a *Plasmodium* species namely the *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium ovale*, *Plasmodium malariae*, and rarely *Plasmodium knowlesi* in human.² Majority of the death due to malaria is caused by *P. falciparum* because *P. falciparum* is the most common cause of malarial infection.³

As per the World Health Organization (WHO), malaria due to *P. falciparum* commonly presents with jaundice (bilirubin ≥ 3 mg/ dl) and involves the liver.⁴

Several studies suggest that hematologic and biochemical changes blood and there are common complications associated with this disease. Hematological changes associated with malaria ranges from anemia, thrombo-cytopenia, to life threatening condition known as disseminated intravascular coagulation (DIC) [5– 7]. Changes in haematological parameters of *P. falciparum* may vary with severity of malaria and extent of parasitaemia endemicity, presence of haemoglobinopathies, nutritional status, demographic factors, and level of malaria immunity [8, 9].

Liver involvement in malaria is common in patients of severe malaria. Hepatocytes are affected by the malarial sporozoites lead to organ congestion, sinusoidal blockage, and cellular inflammation. These changes in hepatocytes may cause leakage of parenchymal enzymes and membranous enzymes (transaminases and alkaline phosphatase) into circulation leading to elevation in liver enzymes AST, ALT, and ALP. Such changes may correlate with the hepatic stage of the parasite's life cycle in human host [10, 11]. Clinically they may manifest as jaundice, hepatomegaly [12]. Hyperbilirubinemia is a common feature of *falciparum* malaria and it may be due to hemolysis of both parasitized and nonparasitized erythrocytes and partly due to liver damage [13]. Therefore, mainly unconjugated bilirubin is increased.

Material and Methods

This retrospective study done in department of pathology MGM Medical and associated Hospital Indore during January 2014 to

December 2014. Data was collected from the records and entered in Microsoft excel. A total of 46 patients diagnosed with *falciparum* malaria were included. The diagnosis of malaria was done by thick and thin film. *Falciparum* malaria was confirmed by gametocytes and other morphological features of parasite. Fields' staining of thin film is used commonly and is fairly sensitive for diagnosing malaria parasite. Hematological parameters and serum levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and bilirubin (total and direct) as test indicators of liver function were studied with respect to the level of parasitaemia.

Malarial Parasite Density Determination: *P. falciparum* parasitaemia was determined in various blood smears stained by field stain. Parasitaemia was calculated based on WHO [14]: low (+) 1–10/100 fields, mild (++) 11–100/100 fields, moderate (+++) 1–10/one field, and high parasitaemia (++++>10/one field).

Hematological Analysis: Blood samples were collected in EDTA vials and tested in the laboratory. Determination of hematological parameters including hemoglobin (Hb) concentration, WBC count, lymphocytes, platelets, and packed cell volume (PCV) using automated hematology analyzer.

Assays of Liver Functions Parameters: Serum aspartate transaminases (AST) and alanine transaminase (ALT) parameters were determined. This assay was done following standard recommendations of the IFCC but was optimized for performance and stability by [15, 16]. Alkaline phosphatase (ALP) parameter was determined using Roche/Hitachi systems automatically by colorimetric assay in accordance with a standardized method.

Results

Of the 46 patients infected with *P. falciparum* 16% had low intensity of infection 1+ (1–10/100 fields), 30% had mild intensity of infection 2+ (11–100/100 fields), 25 % had moderate intensity of infection 3+ (1–10/one field), and 29 % had high intensity of infection 4+ (>10/one field) (Table 1). There were significant decreases in the mean values of the hemoglobin (Hb), packed cell volume (PCV), total leucocyte counts (tWBC), lymphocytes, and

platelets. Neutrophils were significantly higher in patients with *falciparum* malaria in comparison to standard normal values/reference range.

Table 1: Comparison of hematological parameters between the cases of *P. falciparum* malaria infection and reference range.

S.No	Parameters	Patients with malaria (Mean)	Reference Range (mean)
1	Hb (g/dL)	11.6 gm/l	14.5 gm/l
2	PCV (%)	32%	41%
3	T.WBC (per cumm)	6000/cumm	7500/cumm
4	Lymphocytes (%)	20%	31%
5	Neutrophils (%)	62%	60%
6	Platelet (x10 ³ /L)	1,20,000/cumm	3,00,000/cumm

Table 2: Mean total and direct bilirubin levels in parasitaemia *P.falciparum* malaria.

Parasitaemia	Total bilirubin mg/dL	Direct bilirubin mg/dL	Indirect bilirubin mg/dL
Low	2.30 mg/dl	1.64	0.66
Mild	3.47 mg/dl	3.00	1.47
Moderate	5.14 mg/dl	4.10	1.04
High	8.68 mg/dl	6.38	2.30

Table 3: Mean liver enzymes levels in parasitaemia *P.falciparum* malaria patients

Mean parasitaemia/field	AST level (U/L)	ALT level (U/L)	ALP level (U/L)
Low (+)	29.32	23.52	97.69
Mild (+)	35.36	26.89	139.8
Moderate (+)	59.63	48.27	198.4
High (+)	99.13	62.28	234.5

Discussion

In this study, hemoglobin (Hb) and packed cell volume (PCV) decreased in *P. falciparum* affected patients compared. This finding agrees with previous reports [17, 18]. The earlier studies reported a significant reduction in hemoglobin concentration and packed cell volume in patients with malaria parasitaemia. In this study the mean hemoglobin concentration showed 9.3 g/dL, but, in the study done by Nadeem et al. [19], hemoglobin level in *P. falciparum* affected patients was 13.7 gm/dL. This value was more than that observed in our study. Reduced hemoglobin in malaria may be attributed to the increase of breakdown red blood cells by the parasites [20]. According to the report of Maina et al., as contained in the National Guidelines for Diagnosis Treatment and Prevention of Malaria for Health Workers in Kenya, anemia is defined as [Hb] < 10 g/dL for both males and females. Furthermore, severe malarial anemia is defined as [Hb] <5.5 g/dL. Therefore, the drop in hemoglobin concentrations in the malarious subjects in our study ranged between 5 and 10.5 g/dL, ranging approximately from mild to moderate anemia. In study done by Bakhubaira [21]

We found a significant increase in neutrophil counts in patients with *P. falciparum* malaria. Several reports [17,] have found similar findings. Low platelet count which is primarily an attribute of viral haemorrhagic fevers like dengue, may however be more common than anemia in *falciparum* malaria.

The results reported in this study show some significant increases in activities enzymes aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) among patients with *P. falciparum* malaria. The increased serum levels of hepatic enzymes, transaminases (AST and ALT), and ALP are the biomarkers of liver disorders. Our results are consistent with other studies which reported that majority of the patients show elevation in serum activities (AST, ALT, and ALP) indicating liver damage

Conclusion

Acute *falciparum* malaria (irrespective of amount of parasitaemia) is associated with an increase in serum activity of AST and ALThighlighting the fact that the infection is associated with hepatic damage. Patients with moderate and high parasitaemia affects the Hemoglobin, platelet count, causes leucopaenia, and neutrophilia. Therefore, monitoring blood parameters and hepatic function is very important for therapeutic work up, as it enables the clinician to establish reliable and prompt diagnostic protocols and help ensure adequate therapeutic interventions and effective follow up.

References:

- Casals-Pascual C, Roberts DJ. Malaria and the red cell. *Vox Sang* 2004;87 Suppl 2:1159.
- Mueller I, Zimmerman PA, Reeder JC. *Plasmodium malariae* and *Plasmodium ovale* – The “bashful” malaria parasites. *Trends Parasitol* 2007;23:278-83.
- Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of *Plasmodium vivax* malaria. *Am J Trop Med Hyg* 2001;64:97-106.
- Severe *falciparum* malaria. World Health Organization, communicable diseases cluster. *Trans R Soc Trop Med Hyg* 2000;94 Suppl 1:S1-90.
- C. A. Facer, “Hematological aspects of malaria,” in *Infection and Hematology*, Butterworth Heinemann, Oxford, UK, 1994.
- R. N. Maina, D. Walsh, C. Gaddy et al., “Impact of *Plasmodium falciparum* infection on haematological parameters in children living in Western Kenya,” *Malaria Journal*, vol. 9, no. 3, article S4, 2010.
- S. Chandra and H. Chandra, “Role of haematological parameters as an indicator of acute malarial infection in Uttarakhand state of India,” *Mediterranean Journal of Hematology and Infectious Diseases*, vol. 5, no. 1, Article ID e2013009, 2013.
- R. N. Price, J. A. Simpson, F. Nosten et al., “Factors contributing to anemia after uncomplicated *falciparum* malaria,” *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 5, pp. 614–622, 2001.
- L. M. Erhart, K. Yingyuen, N. Chuanak et al., “Hematologic and clinical indices of malaria in a semi-immune population of Western Thailand,” *American Journal of Tropical Medicine and Hygiene*, vol. 70, no. 1, pp. 8–14, 2004.
- C. Burtis, E. Ashwood, and B. Border, “Liver functions,” in *Tietz Fundamentals of Clinical Chemistry*, pp. 748–770, Saunders Company, Philadelphia, Pa, USA, 5th edition, 2001.
- I. Onyesom, “Activities of some liver enzymes in serum of *P. falciparum* malarial infected humans receiving artemisinin and non-artemisinin-based combination therapy,” *Annals of Biological Research*, vol. 3, no. 7, pp. 3097–3100, 2012.
- R. Baheti, P. Laddha, and R. S. Gehlot, “Liver Involvement in *falciparum* malaria—a histo-pathological analysis,” *Journal, Indian Academy of Clinical Medicine*, vol. 4, no. 1, pp. 34–38, 2003.
- T. Harinasuta and D. Bunnag, “The clinical features of malaria,” in *Malaria: Principles and Practice of Malariology*, W. H. Wernsdorfer and I. A. McGregor, Eds., vol. 1, pp. 709–732, Churchill Livingstone, Edinburgh, UK, 1988.
- WHO, *Basic Malaria Microscopy: Part 1 Learner’s Guide*, World Health Organization, Geneva, Switzerland, 1991.
- H. U. Bergmeyer, M. Horder, and R. Rej, “Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase,” *Journal of Clinical Chemistry and Clinical Biochemistry*, vol. 24, pp. 497–510, 1986.
- ECCLS, “Determination of the catalytic activity concentration in serum of L-aspartate aminotransferase (EC 2.6.1.1, ASAT),” *Klinische Chemie Mitteilungen*, vol. 20, pp. 198–204, 1989.
- R. N. Maina, D. Walsh, C. Gaddy et al., “Impact of *Plasmodium falciparum* infection on haematological parameters in children living in Western Kenya,” *Malaria Journal*, vol. 9, no. 3, article S4, 2010.
- O. I. George and C. S. Ewelike-Ezeani, “Haematological changes in children with malaria infection in Nigeria,” *Journal of Medicine and Medical Sciences*, vol. 2, no. 4, pp. 768–771, 2011.
- M. Nadeem, N. Ali, and M. A. Qamar, “Hematological findings in acute malarial infection list of authors along with highest qualification and institute,” *Biomedica*, vol. 18, pp. 62–65, 2002.
- O. N. Goselle, C. O. E. Onwuliri, and V. A. Onwuliri, “Malaria infection in HIV/AIDS patients and its correlation with packed cell volume (PCV),” *Journal of Vector Borne Diseases*, vol. 46, no. 3, pp. 205–211, 2009.
- S. Bakhubaira, “Hematological parameters in severe compli-cated *Plasmodium falciparum* malaria among adults in Aden,” *Turkish Journal of Hematology*, vol. 30, no. 4, pp. 394–399, 2013